Trial intelligence / Profile preview

RC278 in advanced solid tumors

NCT07105215Phase 2Recruiting

Sponsor
RemeGen
Start
Aug 2025
Primary completion
Dec 2027
Modality
Antibody-Drug Conjugates (ADCs)
Countries
1
01

Overview

A Phase 2 trial of RC278 in solid tumor, sponsored by RemeGen. Started Aug 2025; status: recruiting.

02

Drugs

RC278
03

Conditions

solid tumor

Beyond the preview

Go deeper on NCT07105215.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT07105215.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call